Novel therapeutic strategies are envisaged after testing the use of MKK1/2 inhibitor MKK162, which show effectiveness in a mouse model of corticotroph tumor causal of Cushing’s disease, reducing tumor growth and tumor-derived circulating levels of ACTH and, hence, corticosterone [65]. Here, MAP2K1 is linked to neoplasm.